Man who called 2020 Crash warns of huge event in 2022
A historic event in 2022 will cause a massive shift in the wealth divide. It could leave thousands of Americans under age 50 better off… while retirees will be left holding the scraps.
Details here…
Alexander Aravanis, insider at Illumina
Alexander Aravanis Insider Alerts

Get notified the next time Alexander Aravanis buys or sells Illumina stock. Enter your email address below to get our daily insider buying and selling report.

Alexander Aravanis Insider Information

SVP of Illumina
Alex Aravanis Ph.D. serves as Chief Technology Officer of the Company. Dr. Aravanis brings almost 20 years of experience in leading research and development efforts, spanning basic research and technology development through late stage clinical development, and is returning to Illumina from GRAIL, Inc. which he co-founded, and serves as the Chief Scientific Officer and Head of Research and Development. At GRAIL, he led the teams developing its multi-cancer early detection test by combining high-intensity sequencing approaches of unprecedented breadth and depth, and the latest tools of data science and data engineering, including powerful approaches from machine learning, such as neural networks. He and the GRAIL team created one of the largest clinical study programs ever in genomic medicine to support development of its products. Prior to GRAIL, Dr. Aravanis served in R&D for Illumina and developed multiple technologies, including clinical assays and bioinformatic pipelines for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics and liquid biopsy using cell-free nucleic acids. Dr. Aravanis holds a B.S. in Electrical Engineering, Computer Science, and Physics Minor from the University of California, Berkeley, as well as an M.S. and Ph.D. in Electrical Engineering, and an M.D. from Stanford University.

How do I contact Alexander Aravanis?

The corporate mailing address for Dr. Aravanis and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]

Has Alexander Aravanis been buying or selling shares of Illumina?

Alexander Aravanis has not been actively trading shares of Illumina over the course of the past ninety days. Most recently, Alexander Aravanis sold 361 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $386.35, for a transaction totalling $139,472.35.

Who are Illumina's active insiders?

Illumina's insider roster includes Alexander Aravanis (SVP), Charles Dadswell (SVP), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), and Susan Tousi (SVP).

Are insiders buying or selling shares of Illumina?

In the last year, insiders at the life sciences company sold shares 36 times. They sold a total of 43,638 shares worth more than $18,041,132.90. The most recent insider tranaction occured on January, 12th when SVP Susan H Tousi sold 800 shares worth more than $340,000.00. Insiders at Illumina own 0.2 % of the company.

Information on this page was last updated on 1/12/2022.

Alexander Aravanis Insider Trading History at Illumina

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2021Sell361$386.35$139,472.35View SEC Filing Icon  
11/2/2021Sell2,926$412.78$1,207,794.28View SEC Filing Icon  
10/26/2021Sell2,926$423.00$1,237,698.00View SEC Filing Icon  
10/19/2021Sell2,926$411.82$1,204,985.32View SEC Filing Icon  
10/12/2021Sell2,926$409.21$1,197,348.46View SEC Filing Icon  
7/7/2021Sell539$477.59$257,421.01View SEC Filing Icon  
See Full Table

Alexander Aravanis Buying and Selling Activity at Illumina

This chart shows Alexander Aravanis's buying and selling at Illumina by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Illumina Company Overview

Illumina logo
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $365.94
Low: $365.78
High: $383.98

50 Day Range

MA: $377.90
Low: $347.28
High: $423.80

2 Week Range

Now: $365.94
Low: $341.03
High: $555.77

Volume

1,057,832 shs

Average Volume

1,287,327 shs

Market Capitalization

$57.20 billion

P/E Ratio

60.09

Dividend Yield

N/A

Beta

0.9
iPhone Warning: This new technology could make the iPhone obsolete
Warning: One day, that shiny new iPhone in your hand will be worthless. And that day isn’t as far away as you think.

Because all the 6.3 billion smartphones on the planet will be replaced by the revolutionary new device in this little black box.
Apple’s CEO has called this “the next big thing”